Classen Immunotherapies, Inc. v. Biogen Idec

659 F.3d 1057

Opinion

United States Court of Appeals for the Federal Circuit ______________________

September 12, 2011 ERRATA ______________________

2006-1634, -1649

CLASSEN IMMUNOTHERAPIES, INC., Plaintiff-Appellant,

v.

BIOGEN IDEC, Defendant-Appellee,

and

GLAXOSMITHKLINE, Defendant-Appellee,

MERCK & CO., INC., Defendant-Cross Appellant,

CHIRON CORPORATION, KAISER-PERMANENTE, INC., KAISER PERMANENTE VENTURES, KAISER PERMANENTE INTERNATIONAL, KAISER PERMANENTE INSURANCE COMPANY, THE PERMANENTE FEDERATION, LLC, THE PERMANENTE COMPANY, LLC, THE PERMANENTE FOUNDATION, THE PERMANENTE MEDICAL GROUP, INC., KAISER FOUNDATION HOSPITALS, KAISER FOUNDATION ADDED CHOICE HEALTH PLAN, INC., and KAISER FOUNDATION HEALTH PLAN INC.,

Defendants. ______________________

Decided August 31, 2011 Precedential Opinion ______________________

Please make the following change:

Page 2, the following corrections

Donald R. Ware, Foley Hoag LLP, of Boston, Massachu- setts, for defendant-appellee, Biogen IDEC. With him on the brief were Barbara A. Fiacco and Jeremy A. Younkin. Of counsel were Joshua M. Hiller, Wilmer Cutler Pickering Hale and Dorr LLP, of Boston, Massachusetts, and David A. Wilson, of Washington, DC.